Prophylactic trimethoprim-sulfamethoxazole during consolidation chemotherapy for acute leukemia: A controlled trial

Barbara Weiser, M. Lange, M. A. Fialk, C. Singer, T. H. Szatrowski, D. Armstrong

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

We conducted a prospective, controlled, randomized trial of oral trimethoprim-sulfamethoxazole treatment in patients with acute leukemia receiving consolidation chemotherapy. We followed 14 treatment patients during 33 episodes and 15 control patients during 34 episodes of granulocytopenia (less than 1000 granulocytes/mm 3). We found no significant difference in the incidence of febrile episodes (13 in treatment group versus 14 in control group), hospitilizations to treat fever or infection (10 versus 12),number of documented infections (8 versus 10), number of septicemias (one versus two), or mean duration of hospital stay to treat fever or infection (8.9 versus 9.2 days) in the two groups. There was little colonization with organisms resistant to trimethoprim-sulfamethoxazole, including Candida, in either group. Prophylactic trimethoprim-sulfamethoxazole did not significantly reduce the incidence of fever, hospitalization, or infection in granulocytopenic patients during consolidation chemotherapy.

Original languageEnglish (US)
Pages (from-to)436-438
Number of pages3
JournalAnnals of Internal Medicine
Volume95
Issue number4
StatePublished - 1981
Externally publishedYes

Fingerprint

Consolidation Chemotherapy
Sulfamethoxazole Drug Combination Trimethoprim
Leukemia
Fever
Infection
Agranulocytosis
Incidence
Candida
Granulocytes
Length of Stay
Sepsis
Hospitalization
Therapeutics
Randomized Controlled Trials
Control Groups

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Weiser, B., Lange, M., Fialk, M. A., Singer, C., Szatrowski, T. H., & Armstrong, D. (1981). Prophylactic trimethoprim-sulfamethoxazole during consolidation chemotherapy for acute leukemia: A controlled trial. Annals of Internal Medicine, 95(4), 436-438.

Prophylactic trimethoprim-sulfamethoxazole during consolidation chemotherapy for acute leukemia : A controlled trial. / Weiser, Barbara; Lange, M.; Fialk, M. A.; Singer, C.; Szatrowski, T. H.; Armstrong, D.

In: Annals of Internal Medicine, Vol. 95, No. 4, 1981, p. 436-438.

Research output: Contribution to journalArticle

Weiser, B, Lange, M, Fialk, MA, Singer, C, Szatrowski, TH & Armstrong, D 1981, 'Prophylactic trimethoprim-sulfamethoxazole during consolidation chemotherapy for acute leukemia: A controlled trial', Annals of Internal Medicine, vol. 95, no. 4, pp. 436-438.
Weiser, Barbara ; Lange, M. ; Fialk, M. A. ; Singer, C. ; Szatrowski, T. H. ; Armstrong, D. / Prophylactic trimethoprim-sulfamethoxazole during consolidation chemotherapy for acute leukemia : A controlled trial. In: Annals of Internal Medicine. 1981 ; Vol. 95, No. 4. pp. 436-438.
@article{fc5943d0408a471f8f6cbe6d2818ab49,
title = "Prophylactic trimethoprim-sulfamethoxazole during consolidation chemotherapy for acute leukemia: A controlled trial",
abstract = "We conducted a prospective, controlled, randomized trial of oral trimethoprim-sulfamethoxazole treatment in patients with acute leukemia receiving consolidation chemotherapy. We followed 14 treatment patients during 33 episodes and 15 control patients during 34 episodes of granulocytopenia (less than 1000 granulocytes/mm 3). We found no significant difference in the incidence of febrile episodes (13 in treatment group versus 14 in control group), hospitilizations to treat fever or infection (10 versus 12),number of documented infections (8 versus 10), number of septicemias (one versus two), or mean duration of hospital stay to treat fever or infection (8.9 versus 9.2 days) in the two groups. There was little colonization with organisms resistant to trimethoprim-sulfamethoxazole, including Candida, in either group. Prophylactic trimethoprim-sulfamethoxazole did not significantly reduce the incidence of fever, hospitalization, or infection in granulocytopenic patients during consolidation chemotherapy.",
author = "Barbara Weiser and M. Lange and Fialk, {M. A.} and C. Singer and Szatrowski, {T. H.} and D. Armstrong",
year = "1981",
language = "English (US)",
volume = "95",
pages = "436--438",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "4",

}

TY - JOUR

T1 - Prophylactic trimethoprim-sulfamethoxazole during consolidation chemotherapy for acute leukemia

T2 - A controlled trial

AU - Weiser, Barbara

AU - Lange, M.

AU - Fialk, M. A.

AU - Singer, C.

AU - Szatrowski, T. H.

AU - Armstrong, D.

PY - 1981

Y1 - 1981

N2 - We conducted a prospective, controlled, randomized trial of oral trimethoprim-sulfamethoxazole treatment in patients with acute leukemia receiving consolidation chemotherapy. We followed 14 treatment patients during 33 episodes and 15 control patients during 34 episodes of granulocytopenia (less than 1000 granulocytes/mm 3). We found no significant difference in the incidence of febrile episodes (13 in treatment group versus 14 in control group), hospitilizations to treat fever or infection (10 versus 12),number of documented infections (8 versus 10), number of septicemias (one versus two), or mean duration of hospital stay to treat fever or infection (8.9 versus 9.2 days) in the two groups. There was little colonization with organisms resistant to trimethoprim-sulfamethoxazole, including Candida, in either group. Prophylactic trimethoprim-sulfamethoxazole did not significantly reduce the incidence of fever, hospitalization, or infection in granulocytopenic patients during consolidation chemotherapy.

AB - We conducted a prospective, controlled, randomized trial of oral trimethoprim-sulfamethoxazole treatment in patients with acute leukemia receiving consolidation chemotherapy. We followed 14 treatment patients during 33 episodes and 15 control patients during 34 episodes of granulocytopenia (less than 1000 granulocytes/mm 3). We found no significant difference in the incidence of febrile episodes (13 in treatment group versus 14 in control group), hospitilizations to treat fever or infection (10 versus 12),number of documented infections (8 versus 10), number of septicemias (one versus two), or mean duration of hospital stay to treat fever or infection (8.9 versus 9.2 days) in the two groups. There was little colonization with organisms resistant to trimethoprim-sulfamethoxazole, including Candida, in either group. Prophylactic trimethoprim-sulfamethoxazole did not significantly reduce the incidence of fever, hospitalization, or infection in granulocytopenic patients during consolidation chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0019446625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019446625&partnerID=8YFLogxK

M3 - Article

C2 - 7025721

AN - SCOPUS:0019446625

VL - 95

SP - 436

EP - 438

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 4

ER -